New study results demonstrate low risk of interactions between SCY-078 and drugs metabolized by CYP enzymes
Results suggest potential clinical relevance of SCY-078 for patients with Type 2 diabetes with VVC
On track to report Phase 2b data in VVC by July 2018, with Phase 3 trial initiation in the fourth quarter of 2018
PR Newswire
JERSEY CITY, N.J., June 6, 2018